BioRegenx, Inc.
BRGX
$0.01
-$0.0039-28.06%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -26.79% | -20.09% | -31.41% | 154.50% | 319.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.79% | -20.09% | -31.41% | 154.50% | 319.99% |
| Cost of Revenue | -52.27% | -34.41% | -38.02% | 174.65% | 377.64% |
| Gross Profit | -13.34% | -13.02% | -28.25% | 145.66% | 294.85% |
| SG&A Expenses | -63.15% | -48.76% | 23.86% | 126.64% | 3,189.75% |
| Depreciation & Amortization | -- | -- | -- | 9,427.12% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.30% | -35.04% | 30.36% | 150.84% | 1,946.58% |
| Operating Income | 59.83% | 41.88% | -92.16% | -148.86% | -3,693.76% |
| Income Before Tax | -173.53% | -209.20% | -540.39% | -182.47% | -2,315.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -173.53% | -209.20% | -540.39% | -182.47% | -2,315.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -173.53% | -209.20% | -540.39% | -182.47% | -2,315.53% |
| EBIT | 59.83% | 41.88% | -92.16% | -148.86% | -3,693.76% |
| EBITDA | 73.24% | 66.68% | -27.24% | -61.34% | -3,051.96% |
| EPS Basic | -102.04% | -121.28% | -331.58% | -69.44% | 14.78% |
| Normalized Basic EPS | 66.67% | 55.17% | -47.06% | -72.73% | 16.67% |
| EPS Diluted | -102.04% | -121.28% | -331.58% | -69.44% | 14.78% |
| Normalized Diluted EPS | 66.67% | 55.17% | -47.06% | -72.73% | 16.67% |
| Average Basic Shares Outstanding | 26.34% | 34.77% | 35.17% | 13.78% | 27.58% |
| Average Diluted Shares Outstanding | 26.34% | 34.77% | 35.17% | 13.78% | 27.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |